Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

RSV is usually contagious for three to eight days. A patient also may be contagious a day or two before experiencing symptoms ...

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

UPMC saw an increase in RSV cases in its health system, including in Lancaster County, a spokesperson said Jan. 7, especially ...

At the start of every week, our team talks with local experts to unpack a wide range of nationwide health, safety, and ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

Tis the season—for the flu, COVID, stomach bugs, and other nasty viruses that can knock us down for several days, causing ...